Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT05507580 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05507580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05507580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
May 29, 2023
Completion date
August 15, 2024
Enrollment
461 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis